Aurobindo Pharma arm CuraTeQ Biologics incorporates new wholly owned subsidiary in Malta We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma reports minor fire incident at Andhra Pradesh unit We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma arm Telangana facility gets 5 USFDA observations We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma in lead to acquire Zentiva for US 5.5 billion: ET Report We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma ramps up China facility production, eyes Q3 FY26 break even We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Aurobindo Pharma net profit drops 10 percent to Rs 824 crore in Q1 We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link